RPS6 and neoplasm: These three combinations were tested in the same way on mice with xenografts of WHIM30, a PTEN deficient PIK3CA wild type basal-like PDX, with the everolimus and BYL-719 combination showing a reduction in tumor growth for each treatment group relative to the vehicle and synergistic effects (p < 0.05 and CDI 0.77) (Figure 10A,B) and everolimus treatment also reduced p-RPS6 in HCI-010 (Supplemental Figure S8).